

# Yoshiya Tanaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2781484/publications.pdf>

Version: 2024-02-01

685  
papers

30,312  
citations

7568

77  
h-index

8396

147  
g-index

777  
all docs

777  
docs citations

777  
times ranked

22907  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome) Trial. <i>Modern Rheumatology</i> , 2023, 33, 145-153.	1.8	4
2	Usefulness of ultrasound as a predictor of elderly-onset rheumatoid arthritis with polymyalgia rheumatica-like onset. <i>Modern Rheumatology</i> , 2023, 33, 318-322.	1.8	5
3	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. <i>Modern Rheumatology</i> , 2023, 33, 64-72.	1.8	2
4	Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study. <i>Modern Rheumatology</i> , 2023, 33, 122-133.	1.8	2
5	Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. <i>Rheumatology</i> , 2023, 62, 617-628.	1.9	9
6	Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region. <i>Arthritis Care and Research</i> , 2022, 74, 187-198.	3.4	25
7	Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. <i>Modern Rheumatology</i> , 2022, 32, 41-49.	1.8	7
8	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , 2022, 32, 59-67.	1.8	6
9	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. <i>Modern Rheumatology</i> , 2022, 32, 1-11.	1.8	21
10	Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 1141-1147.	1.9	8
11	Blood glucose dynamics during sleep in patients with obstructive sleep apnea and normal glucose tolerance: effects of CPAP therapy. <i>Sleep and Breathing</i> , 2022, 26, 771-781.	1.7	4
12	Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. <i>Rheumatology</i> , 2022, 61, 1831-1840.	1.9	14
13	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. <i>Journal of Rheumatology</i> , 2022, 49, 133-141.	2.0	5
14	Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2596-2602.	1.9	4
15	Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 82-93.	4.4	3
16	Low Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Poorly Controlled Type 2 Diabetes: A Retrospective Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 242-251.	2.0	6
17	Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2022, 32, 696-707.	1.8	1

#	ARTICLE	IF	CITATIONS
19	A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. <i>Modern Rheumatology</i> , 2022, 32, 708-717.	1.8	2
20	Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials. <i>Modern Rheumatology</i> , 2022, 32, 686-695.	1.8	2
21	Neuropsychiatric systemic lupus erythematosus detected using extravascular spillage signal on dynamic magnetic resonance imaging (Ktrans). <i>Rheumatology</i> , 2022, 61, SI102-SI104.	1.9	1
22	Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2022, 31, 1082-1095.	2.9	1
23	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 184-192.	0.9	40
24	An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3049-3059.	1.9	19
25	Clinical features of Behçet's disease patients with joint symptoms in Japan: A national multicenter study. <i>Modern Rheumatology</i> , 2022, 32, 1146-1152.	1.8	1
26	Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 191-206.	2.3	4
27	Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: <i>post hoc</i> analysis of a randomized, placebo-controlled, phase 4 study. <i>Modern Rheumatology</i> , 2022, 32, 500-507.	1.8	2
28	Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study. <i>Modern Rheumatology</i> , 2022, 32, 413-421.	1.8	5
29	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). <i>Modern Rheumatology</i> , 2022, 32, 263-272.	1.8	10
30	Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance. <i>Modern Rheumatology</i> , 2022, 32, 508-516.	1.8	2
31	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). <i>Modern Rheumatology</i> , 2022, 32, 273-283.	1.8	3
32	Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. <i>Scientific Reports</i> , 2022, 12, 154.	3.3	3
33	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 133-145.	8.0	193
34	Risk Factor Analysis for Type 2 Diabetes Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 435-445.	4.4	5
35	A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease. <i>Modern Rheumatology Case Reports</i> , 2022, 6, 178-182.	0.7	1
36	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. <i>Rheumatology</i> , 2022, 61, 4273-4285.	1.9	3

#	ARTICLE	IF	CITATIONS
37	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. <i>RMD Open</i> , 2022, 8, e002012.	3.8	50
38	The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. <i>Modern Rheumatology</i> , 2022, , .	1.8	3
39	Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2022, , .	3.0	5
40	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 86-96.	0.8	5
41	Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. <i>Rheumatology</i> , 2022, , .	1.9	0
42	Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2022, 9, 849120.	2.6	14
43	Hypoglycemia induces vascular endothelial dysfunction in subjects with normal glucose tolerance. <i>Scientific Reports</i> , 2022, 12, 2598.	3.3	7
44	Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease. <i>RMD Open</i> , 2022, 8, e002086.	3.8	5
45	A case of mixed connective tissue disease complicated by pulmonary hypertension and ascites after addition of pulmonary vasodilators. <i>Modern Rheumatology Case Reports</i> , 2022, , .	0.7	1
46	Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. <i>Arthritis Research and Therapy</i> , 2022, 24, 61.	3.5	30
47	Dawn of Precision Medicine in Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2022, 9, 851892.	2.6	3
48	“Not at target”: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	3.5	17
49	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 951-961.	0.9	38
50	Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). <i>Modern Rheumatology</i> , 2022, , .	1.8	3
51	Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. <i>Rheumatology</i> , 2022, 61, 4875-4884.	1.9	5
52	Short-Term Prognostic Factors in Hospitalized Herpes Zoster Patients and Its Associated Cerebro-Cardiovascular Events: A Nationwide Retrospective Cohort in Japan. <i>Frontiers in Medicine</i> , 2022, 9, 843809.	2.6	3
53	Allogeneic Stem Cell Transplantation for Trisomy 8-Positive Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Disease with Refractory Behçet’s Disease, Case Report and the Review of Literature. <i>Modern Rheumatology Case Reports</i> , 2022, , .	0.7	1
54	Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109836.	2.8	5

#	ARTICLE	IF	CITATIONS
55	A patient with eosinophilic granulomatosis with polyangiitis successfully weaned from corticosteroids through remission induction therapy with mepolizumab. <i>Modern Rheumatology Case Reports</i> , 2022, 6, 243-247.	0.7	7
56	Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3614-3626.	1.9	10
57	Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis. <i>Modern Rheumatology</i> , 2022, 32, 1077-1085.	1.8	1
58	Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. <i>Arthritis Research and Therapy</i> , 2022, 24, 86.	3.5	5
59	Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab. <i>Modern Rheumatology Case Reports</i> , 2022, , .	0.7	2
60	P192â€fEfficacy of filgotinib in rheumatoid arthritis by age, body weight, body mass index: post hoc subgroup analysis of two phase 3 trials. <i>Rheumatology</i> , 2022, 61, .	1.9	0
61	OA29â€fClinical outcomes up to week 48 of filgotinib treatment in an ongoing long-term extension trial of RA patients with inadequate response to methotrexate initially treated with filgotinib or adalimumab during the Phase 3 Parent Trial. <i>Rheumatology</i> , 2022, 61, .	1.9	1
62	P220â€fLong-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. <i>Rheumatology</i> , 2022, 61, .	1.9	1
63	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 962-969.	0.9	15
64	Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1267-1272.	0.9	18
65	Phase II/III Results of a Trial of Antiâ€Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 1776-1785.	5.6	25
66	Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis. , 2022, 1, 32.		0
67	Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1301-1312.	0.9	21
68	Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	10
69	Association Between Time in Range and Postprandial Glucose Contribution Rate in Non-Insulin-Treated Type 2 Diabetes Patients: Inverse Correlation of Time in Range with Postprandial Glucose Contribution Rate. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 805-813.	4.4	2
70	Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1556-1563.	0.9	24
71	Response to: â€Comment on â€Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trialâ€™ by Tanaka <i>et al</i>â€™ by Berkhout <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e173-e173.	0.9	0
72	Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-IX study. <i>Rheumatology</i> , 2021, 60, 2884-2895.	1.9	14

#	ARTICLE	IF	CITATIONS
73	Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. <i>Modern Rheumatology</i> , 2021, 31, 94-100.	1.8	8
74	Case of autoimmune polyendocrine syndrome type 3 complicated with anti-CD40L (CD137) receptor encephalitis. <i>Journal of Diabetes Investigation</i> , 2021, 12, 290-292.	2.4	0
75	A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate. <i>Modern Rheumatology</i> , 2021, 31, 53-60.	1.8	2
76	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
77	Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021, 73, 132-142.	5.6	48
78	Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 11-15.	0.7	4
79	Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 587-595.	5.6	17
80	RANKL as a therapeutic target of rheumatoid arthritis. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 106-112.	2.7	30
81	Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. <i>Bone</i> , 2021, 142, 115616.	2.9	19
82	A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. <i>Modern Rheumatology</i> , 2021, 31, 543-555.	1.8	6
83	Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 446-455.	2.7	9
84	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. <i>Rheumatology</i> , 2021, 60, 2256-2266.	1.9	12
85	Lung transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: a case report. <i>Rheumatology</i> , 2021, 60, e129-e131.	1.9	0
86	Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. <i>Osteoporosis International</i> , 2021, 32, 817-829.	3.1	21
87	Why remission is not enough: underlying disease mechanisms in RA that prevent cure. <i>Nature Reviews Rheumatology</i> , 2021, 17, 135-144.	8.0	49
88	Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2021, 12, 601-609.	2.4	7
89	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 304-311.	0.9	129
90	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. <i>Rheumatology</i> , 2021, 60, 820-828.	1.9	41

#	ARTICLE	IF	CITATIONS
91	Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. <i>Modern Rheumatology</i> , 2021, 31, 1-12.	1.8	52
92	Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. <i>Modern Rheumatology</i> , 2021, 31, 34-41.	1.8	14
93	Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. <i>Modern Rheumatology</i> , 2021, 31, 42-52.	1.8	6
94	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. <i>Modern Rheumatology</i> , 2021, 31, 29-33.	1.8	49
95	Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. <i>Rheumatology</i> , 2021, 60, vi12-vi20.	1.9	26
96	&lt;i>&gt;SOD2&lt;/i> mRNA as a potential biomarker for exercise: interventional and cross-sectional research in healthy subjects. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 69, 137-144.	1.4	2
97	Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study. <i>Endocrine Journal</i> , 2021, 68, 361-369.	1.6	2
98	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , 2021, 7, e001465.	3.8	9
99	Efficacy and safety of upadacitinib over 84&#x2013;weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). <i>Arthritis Research and Therapy</i> , 2021, 23, 9.	3.5	17
100	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. <i>Modern Rheumatology</i> , 2021, 31, 783-789.	1.8	11
101	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
102	Upadacitinib in Rheumatoid Arthritis: A Benefit&#x2013;Risk Assessment Across a Phase III Program. <i>Drug Safety</i> , 2021, 44, 515-530.	3.2	28
103	Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1655-1662.	2.0	10
104	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring. <i>Scientific Reports</i> , 2021, 11, 4875.	3.3	5
105	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <i>Lancet Rheumatology</i> , The, 2021, 3, e517-e531.	3.9	26
106	Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. <i>RMD Open</i> , 2021, 7, e001508.	3.8	17
107	Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 729-750.	2.3	6
108	Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 5452-5462.	1.9	7

#	ARTICLE	IF	CITATIONS
109	Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. <i>Journal of Clinical Medicine</i> , 2021, 10, 1241.	2.4	25
110	Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan. <i>Rheumatology and Therapy</i> , 2021, 8, 425-442.	2.3	16
111	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. <i>Arthritis Research and Therapy</i> , 2021, 23, 86.	3.5	22
112	A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 285-291.	0.7	4
113	Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1130-1136.	0.9	33
114	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. <i>Journal of Rheumatology</i> , 2021, 48, 1663-1671.	2.0	10
115	Stimulator of Interferon Genes-associated Vasculopathy with an Onset in Infancy Diagnosed after the Development of Atypical Pulmonary Lesions During Treatment as Juvenile Idiopathic Arthritis. <i>Internal Medicine</i> , 2021, 60, 1109-1114.	0.7	4
116	Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 45.	2.7	5
117	The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. <i>Drug Safety</i> , 2021, 44, 711-722.	3.2	15
118	Fatal hemoperitoneum due to rupture of mesenteric artery in remission state of microscopic polyangiitis, concomitant with severe hypertension and posterior reversible encephalopathy syndrome: an autopsy case report. <i>CEN Case Reports</i> , 2021, 10, 549-558.	0.9	1
119	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 880-895.	1.9	11
120	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 733-745.	1.9	24
121	Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases. <i>Inflammation and Regeneration</i> , 2021, 41, 14.	3.7	17
122	Work Environment-related Stress Factors are Correlated with Diabetes Development in Workers with Impaired Glucose Tolerance: A 5-year Follow-up Study Using the Brief Job Stress Questionnaire (BJSQ). <i>Journal of UOEH</i> , 2021, 43, 183-196.	0.6	2
123	Validity of claims-based algorithms for selected cancers in Japan: Results from the VALIDATE study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1153-1161.	1.9	18
124	Serum TNF $\alpha$ levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. <i>Arthritis Research and Therapy</i> , 2021, 23, 154.	3.5	6
125	Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. <i>RMD Open</i> , 2021, 7, e001629.	3.8	17
126	Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 221.	3.5	7



#	ARTICLE	IF	CITATIONS
127	Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. <i>Journal of Autoimmunity</i> , 2021, 122, 102680.	6.5	14
128	Therapeutic perspectives on the metabolism of lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1121-1130.	3.0	3
129	A Japanese Patient with Anti-PM/Scl and Centromere Antibody-Positive Scleroderma-Amyopathic Dermatomyositis Overlap Syndrome Who Developed Renal Crisis. <i>Modern Rheumatology Case Reports</i> , 2021, , .	0.7	1
130	Genome-oriented treatment strategies for autoimmune diseases. <i>Inflammation and Regeneration</i> , 2021, 41, 30.	3.7	0
131	Clinical relevance of T follicular helper cells in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1143-1150.	3.0	9
132	Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review. <i>Arthritis Research and Therapy</i> , 2021, 23, 3.	3.5	18
133	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.9	123
134	Subclinical synovitis detected by magnetic resonance imaging and ultrasonography following clinical remission in patients with rheumatoid arthritis: A retrospective study. <i>Rheumatology &amp; Autoimmunity</i> , 2021, 1, 7-15.	0.8	1
135	mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors. <i>Rheumatology</i> , 2021, , .	1.9	4
136	Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study. <i>BMC Rheumatology</i> , 2021, 5, 49.	1.6	0
137	Discovery of a novel Ig <sup>g</sup> 2 and Fc <sup>g</sup> 3RIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2021, 101, 108343.	3.8	0
138	Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study. <i>Modern Rheumatology</i> , 2021, , .	1.8	0
139	Eplerenone Improves Vascular Endothelial Function in Patients with Primary Aldosteronism: A Pilot Study. <i>Journal of UOEH</i> , 2021, 43, 379-384.	0.6	0
140	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
141	Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
142	T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease. <i>Rheumatology</i> , 2021, , .	1.9	1
143	Rituximab in remission induction and maintenance therapy for microscopic polyangiitis associated with gastric cancer: A case report. <i>Modern Rheumatology Case Reports</i> , 2021, , .	0.7	0
144	Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 302.	3.5	12

#	ARTICLE	IF	CITATIONS
145	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020, 30, 36-43.	1.8	44
146	Safety and tolerability of sifalimumab, an anti-interferon- $\gamma$ monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. <i>Modern Rheumatology</i> , 2020, 30, 93-100.	1.8	23
147	Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. <i>Modern Rheumatology</i> , 2020, 30, 101-108.	1.8	26
148	Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice. <i>Journal of Orthopaedic Science</i> , 2020, 25, 331-337.	1.1	5
149	Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. <i>Modern Rheumatology</i> , 2020, 30, 313-320.	1.8	11
150	Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD. <i>Modern Rheumatology</i> , 2020, 30, 551-557.	1.8	5
151	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. <i>Modern Rheumatology</i> , 2020, 30, 525-531.	1.8	6
152	Predictive value of serum amyloid A levels for requirement of concomitant methotrexate in tocilizumab initiation: A <i>post hoc</i> analysis of the SURPRISE study. <i>Modern Rheumatology</i> , 2020, 30, 442-449.	1.8	2
153	Focal Eosinophilic Myositis. <i>Internal Medicine</i> , 2020, 59, 141-141.	0.7	1
154	Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). <i>Modern Rheumatology</i> , 2020, 30, 239-248.	1.8	17
155	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and 12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. <i>Modern Rheumatology</i> , 2020, 30, 424-433.	1.8	1
156	A case of systemic lupus erythematosus in which Cushing's syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 34-38.	0.7	1
157	Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: A multicenter prospective study. <i>Modern Rheumatology</i> , 2020, 30, 821-827.	1.8	7
158	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 387-392.	0.9	17
159	An autopsy case of a patient with systemic sclerosis who developed marked pulmonary hypertension because of pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 56-62.	0.7	1
160	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 94-102.	0.9	13
161	Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 65-73.	1.9	12
162	Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 199-206.	3.0	7

#	ARTICLE	IF	CITATIONS
163	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2020, 382, 211-221.	27.0	725
164	5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. <i>Modern Rheumatology</i> , 2020, 30, 799-806.	1.8	5
165	In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. <i>Rheumatology</i> , 2020, 59, 1957-1968.	1.9	20
166	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 7-19.	5.6	292
167	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. <i>Inflammation and Regeneration</i> , 2020, 40, 16.	3.7	12
168	Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments. <i>Immunological Medicine</i> , 2020, 44, 1-10.	2.6	3
169	P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. <i>Rheumatology</i> , 2020, 59, .	1.9	1
170	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020, 7, e000424.	2.7	35
171	&lt;p&gt;Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases&lt;/p&gt;. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 241-253.	5.8	15
172	Su1862 POOLED SAFETY ANALYSES FROM PHASE 3 STUDIES OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Gastroenterology</i> , 2020, 158, S-679.	1.3	0
173	O09 Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA. <i>Rheumatology</i> , 2020, 59, .	1.9	0
174	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. <i>RMD Open</i> , 2020, 6, e001249.	3.8	8
175	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
176	Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study. <i>Lupus</i> , 2020, 29, 1902-1913.	1.6	14
177	Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus. <i>Scientific Reports</i> , 2020, 10, 15384.	3.3	5
178	O8 Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
179	Rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2020, 40, 20.	3.7	52
180	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1255-1257.	1.9	12

#	ARTICLE	IF	CITATIONS
181	Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case report. <i>Lupus</i> , 2020, 29, 1955-1960.	1.6	5
182	A wide perspective of targeted therapies for precision medicine in autoimmune diseases. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 447-453.	0.7	3
183	Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 70.	2.7	4
184	Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN- $\gamma$ Overproduction in T Helper 1 Cells. <i>Frontiers in Immunology</i> , 2020, 11, 593103.	4.8	12
185	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020, 6, e001395.	3.8	100
186	ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2020, 22, 252.	3.5	10
187	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 115.	3.5	11
188	P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme. <i>Rheumatology</i> , 2020, 59, .	1.9	2
189	Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. <i>Rheumatology</i> , 2020, 59, 3058-3069.	1.9	15
190	Fulminant Type 1 Diabetes with Diversity in Peripheral Blood Lymphocytes: A Case Report. <i>Journal of UOEH</i> , 2020, 42, 57-62.	0.6	0
191	Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 717-722.	1.9	21
192	A review of upadacitinib in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020, 30, 779-787.	1.8	35
193	Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. <i>Arthritis Research and Therapy</i> , 2020, 22, 141.	3.5	10
194	Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 229-232.	0.7	1
195	Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. <i>Arthritis Research and Therapy</i> , 2020, 22, 136.	3.5	16
196	State-of-the-art treatment of systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 465-471.	1.9	85
197	Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 522-532.	2.7	20
198	Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. <i>Arthritis Research and Therapy</i> , 2020, 22, 47.	3.5	21

#	ARTICLE	IF	CITATIONS
199	Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 176-180.	0.7	1
200	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 41.	3.5	10
201	A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor- $\alpha$ (TNF- $\alpha$ ) inhibitor, adalimumab. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 196-201.	0.7	2
202	A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 278-282.	0.7	2
203	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 532-539.	1.9	13
204	Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening. <i>Endocrine Journal</i> , 2020, 67, 509-513.	1.6	3
205	Tumour necrosis factor alpha promotes secretion of 14-3-3 $\sigma$ by inducing necroptosis in macrophages. <i>Arthritis Research and Therapy</i> , 2020, 22, 24.	3.5	16
206	Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. <i>Rheumatology</i> , 2020, 59, 2427-2434.	1.9	81
207	Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 511-521.	2.7	3
208	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 316-324.	1.9	4
209	Methionine Commits Cells to Differentiate Into Plasmablasts Through Epigenetic Regulation of BTB and CNC Homolog 2 by the Methyltransferase EZH2. <i>Arthritis and Rheumatology</i> , 2020, 72, 1143-1153.	5.6	28
210	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 549-558.	1.9	10
211	Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1015-1025.	1.8	22
212	Five Cases of IgG4-related Disease with Nasal Mucosa and Sinus Involvement. <i>Internal Medicine</i> , 2020, 59, 1905-1911.	0.7	7
213	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. <i>Rheumatology</i> , 2020, 59, 3303-3313.	1.9	41
214	Response to: "Some concerns from Turkey" by Bilgin <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e16-e16.	0.9	3
215	A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various psychiatric symptoms and MRI observations. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2020, 11, 1-4.	0.3	0
216	The approach to precision medicine for the treatment of psoriatic arthritis. <i>Immunological Medicine</i> , 2020, 43, 98-102.	2.6	6

#	ARTICLE	IF	CITATIONS
217	Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. <i>Arthritis Research and Therapy</i> , 2020, 22, 72.	3.5	36
218	Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 253-261.	0.7	1
219	IgG4-type Multiple Myeloma with Diffuse Enlargement of the Thyroid Requiring Differentiation from IgG4-related Disease. <i>Internal Medicine</i> , 2020, 59, 711-714.	0.7	4
220	P-glycoprotein Expressing-B cell associated Active True Renal Lupus Vasculitis in Lupus Nephritis. , 2020, 5, .		1
221	Correlations Between Glycemic Parameters Obtained from Continuous Glucose Monitoring and Hemoglobin A1c and Glycoalbumin Levels in Type 2 Diabetes Mellitus. <i>Journal of UOEH</i> , 2020, 42, 299-306.	0.6	2
222	Predicting Disease Activity for Biologic Selection in Rheumatoid Arthritis. , 2020, , .		0
223	Hyperparathyroidism Which Developed after Resection of a Fibroblast Growth Factor 23-producing Tumor. <i>Internal Medicine</i> , 2020, 59, 2523-2527.	0.7	0
224	Mild Encephalitis/Encephalopathy with Reversible Splenic Lesions in SLE. <i>Internal Medicine</i> , 2020, 59, 2439-2440.	0.7	2
225	<i>Internal Medicine</i> , 2020, 109, 1748-1758.	0.0	0
226	Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 670-679.	0.8	3
227	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 848-857.	0.8	6
228	Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases. <i>Neuroendocrinology Letters</i> , 2020, 41, 10-16.	0.2	0
229	Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. <i>Modern Rheumatology</i> , 2019, 29, 452-460.	1.8	13
230	<sc>Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling. <i>Modern Rheumatology</i> , 2019, 29, 885-891.	1.8	17
231	Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. <i>Rheumatology</i> , 2019, 58, 70-79.	1.9	13
232	Effectiveness and safety of initiating adalimumab plus 12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. <i>Modern Rheumatology</i> , 2019, 29, 572-580.	1.8	7
233	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
234	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098

#	ARTICLE	IF	CITATIONS
235	Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10. <i>Bone</i> , 2019, 128, 115034.	2.9	26
236	Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium <sup>+</sup> Glucose Cotransporter 2 Inhibitor. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 385-392.	4.4	2
237	A Case of Marine-Lenhart Syndrome with Predominance of Plummer Disease. <i>Journal of UOEH</i> , 2019, 41, 165-170.	0.6	3
238	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. <i>Case Reports in Rheumatology</i> , 2019, 2019, 1-5.	0.6	8
239	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 164.	3.5	24
240	Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp <sup>+</sup> CD4 <sup>+</sup> Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis. <i>Internal Medicine</i> , 2019, 58, 3173-3178.	0.7	1
241	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1305-1319.	0.9	95
242	An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. <i>Internal Medicine</i> , 2019, 58, 1023-1027.	0.7	4
243	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	5.6	64
244	Baricitinib for systemic lupus erythematosus – Authors' reply. <i>Lancet, The</i> , 2019, 393, 402-403.	13.7	5
245	Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. <i>Advances in Therapy</i> , 2019, 36, 691-707.	2.9	11
246	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 2273-2283.	1.9	22
247	Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behçet's disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 151.	3.5	13
248	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , 2019, 5, e000898.	3.8	14
249	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet, The</i> , 2019, 393, 2303-2311.	13.7	237
250	A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis. <i>Internal Medicine</i> , 2019, 58, 1383-1390.	0.7	11
251	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 890-898.	0.9	22
252	Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases <sup>o</sup> . <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1146-1150.	3.4	18

#	ARTICLE	IF	CITATIONS
253	Addition of canagliflozin to insulin improves glycaemic control and reduces insulin dose in patients with type 2 diabetes mellitus: A randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2174-2179.	4.4	3
254	<i>Small Molecules.</i> , 2019, , 629-637.		0
255	Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 693-700.	3.0	31
256	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 6 2019, 78, 899-907.	0.9	105
257	Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. <i>Arthritis Research and Therapy</i> , 2019, 21, 79.	3.5	28
258	Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1094-1106.	1.9	12
259	Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine. <i>Current Rheumatology Reports</i> , 2019, 21, 21.	4.7	3
260	The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?. <i>Rheumatology</i> , 2019, 58, i1-i3.	1.9	21
261	Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study. <i>BMC Cancer</i> , 2019, 19, 174.	2.6	4
262	Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2019, 10, 1127-1132.	2.5	5
263	IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2. <i>Bone</i> , 2019, 124, 53-61.	2.9	65
264	Expression of the genes encoding hypothalamic feeding-related neuropeptides in the streptozotocin-induced diabetic rats with variable hyperglycemia and hyperphagia. <i>Neuropeptides</i> , 2019, 75, 34-40.	2.2	2
265	Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 18.	2.7	1
266	Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance. <i>Clinical Imaging</i> , 2019, 55, 140-143.	1.5	5
267	AB0416...A COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF YLB113 AND ETANERCEPT REFERENCE PRODUCT FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. , 2019, , .		0
268	SAT0126...A PHASE 2 STUDY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO BIOLOGICS. , 2019, , .		0
269	THU0193...EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (<math>\leq 2</math> YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY. , 2019, , .		3
270	THU0191...UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-MONOTHERAPY STUDY. , 2019, , .		1



#	ARTICLE	IF	CITATIONS
271	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1320-1332.	0.9	85
272	Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1 $\beta$ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy. <i>Internal Medicine</i> , 2019, 58, 427-431.	0.7	3
273	Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. <i>Modern Rheumatology</i> , 2019, 29, 747-755.	1.8	17
274	Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2019, 200, 1-9.	3.2	11
275	The front line of research into immunoglobulin G4-related disease - Do autoantibodies cause immunoglobulin G4-related disease?. <i>Modern Rheumatology</i> , 2019, 29, 214-218.	1.8	25
276	Scleroderma in an ice-cream shop worker. <i>Rheumatology</i> , 2019, 58, 1120-1121.	1.9	1
277	Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2019, 58, 120-130.	1.9	19
278	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. <i>Rheumatology</i> , 2019, 58, 997-1005.	1.9	16
279	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 425-433.	1.9	24
280	Response to $\alpha$ -Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment by Lee. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e134-e134.	0.9	0
281	The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects. <i>Modern Rheumatology Case Reports</i> , 2019, 3, 114-118.	0.7	2
282	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 434-442.	1.9	17
283	Immunophenotype involved in IgG4-related disease. <i>Modern Rheumatology</i> , 2019, 29, 226-230.	1.8	17
284	Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. <i>Modern Rheumatology</i> , 2019, 29, 767-774.	1.8	10
285	Clinical immunity in bone and joints. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 2-8.	2.7	45
286	Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept. <i>Internal Medicine</i> , 2019, 58, 585-591.	0.7	6
287	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. <i>Modern Rheumatology</i> , 2019, 29, 756-766.	1.8	10
288	Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). <i>Modern Rheumatology</i> , 2019, 29, 306-313.	1.8	3

#	ARTICLE	IF	CITATIONS
289	Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1648-1658.	4.3	8
290	Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. <i>Rheumatology</i> , 2019, 58, 336-344.	1.9	92
291	State-of-the-art Internal Medicine in Joints and Bone. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 104a-111a.	0.0	0
292	Society of Internal Medicine, 2019, 108, 393-400.	0.0	0
293	3. State-of-the-art Internal Medicine in Joints and Bone. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1700-1712.	0.0	0
294	Intracranial vessel wall lesions in patients with systematic lupus erythematosus. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1237-1246.	3.4	12
295	Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. <i>Clinical Immunology</i> , 2018, 191, 67-74.	3.2	12
296	Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezumab as a treatment for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2018, 28, 986-992.	1.8	50
297	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 602-611.	0.9	51
298	Clinical practice guideline for Sjögren's syndrome 2017. <i>Modern Rheumatology</i> , 2018, 28, 383-408.	1.8	44
299	Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. <i>Modern Rheumatology</i> , 2018, 28, 941-949.	1.8	3
300	Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials. <i>Modern Rheumatology</i> , 2018, 28, 950-959.	1.8	14
301	Determinants of Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. <i>Modern Rheumatology</i> , 2018, 28, 960-967.	1.8	19
302	Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis. <i>Histopathology</i> , 2018, 72, 1084-1092.	2.9	9
303	Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease. <i>Rheumatology</i> , 2018, 57, 514-524.	1.9	59
304	A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 355-363.	0.9	196
305	Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 140-146.	4.4	23
306	Comparison of the Effects of Tenziglipitin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus. <i>Journal of UOEH</i> , 2018, 40, 1-9.	0.6	2

#	ARTICLE	IF	CITATIONS
307	Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring. <i>Journal of UOEH</i> , 2018, 40, 11-18.	0.6	7
308	Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. <i>Current Opinion in Pharmacology</i> , 2018, 40, 110-119.	3.5	63
309	Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren's syndrome. <i>Respiratory Medicine</i> , 2018, 137, 95-102.	2.9	44
310	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1950-1959.	0.7	183
311	Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. <i>Modern Rheumatology</i> , 2018, 28, 20-29.	1.8	33
312	Design characteristics of the Corona Japan rheumatoid arthritis registry. <i>Modern Rheumatology</i> , 2018, 28, 95-100.	1.8	2
313	Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring. <i>Journal of Diabetes Investigation</i> , 2018, 9, 75-82.	2.4	8
314	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 164-174.	1.9	70
315	A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. <i>Modern Rheumatology</i> , 2018, 28, 76-84.	1.8	17
316	Safety, pharmacokinetics, and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 58-65.	1.8	54
317	Relevance of P-glycoprotein on CXCR4 <sup>+</sup> B cells to organ manifestation in highly active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 276-286.	1.8	14
318	Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. <i>Modern Rheumatology</i> , 2018, 28, 39-47.	1.8	5
319	Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients. <i>Journal of Diabetes Investigation</i> , 2018, 9, 360-365.	2.4	10
320	RANKL: A therapeutic target for bone destruction in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 9-16.	1.8	63
321	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. <i>Modern Rheumatology</i> , 2018, 28, 770-779.	1.8	5
322	Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 348-354.	0.9	279
323	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). <i>Modern Rheumatology</i> , 2018, 28, 642-648.	1.8	16
324	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. <i>Modern Rheumatology</i> , 2018, 28, 583-591.	1.8	36

#	ARTICLE	IF	CITATIONS
325	B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2018, 186, 21-25.	3.2	32
326	Glycemic Profiling in Patients with Drug-Naïve Type 2 Diabetes by Continuous Glucose Monitoring. <i>Journal of UOEH</i> , 2018, 40, 287-297.	0.6	0
327	The role of nailfold videocapillaroscopy in patients with systemic sclerosis. <i>Immunological Medicine</i> , 2018, 41, 113-119.	2.6	9
328	Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem Cells. <i>Critical Reviews in Immunology</i> , 2018, 38, 471-478.	0.5	4
329	Abatacept in combination with methotrexate in Japanese biologic-naïve patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. <i>RMD Open</i> , 2018, 4, e000813.	3.8	11
330	Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 2901.	4.8	58
331	The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy. <i>Internal Medicine</i> , 2018, 57, 65-70.	0.7	9
332	Tocilizumab in patients with adult-onset stillé™s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1720-1729.	0.9	129
333	Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. <i>Arthritis Research and Therapy</i> , 2018, 20, 240.	3.5	39
334	Up-Regulation of TLR7-Mediated IFN-Î± Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 1957.	4.8	66
335	Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1609-1618.	1.9	35
336	Risk Factors for Hypoglycemic Coma: A Study of 33 Patients on Insulin Therapy Who Were Transported to the Hospital by Ambulance. <i>Internal Medicine</i> , 2018, 57, 2923-2927.	0.7	0
337	IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. <i>Internal Medicine</i> , 2018, 57, 2251-2257.	0.7	23
338	Successful Management of Pregnancy in a Patient with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension. <i>Internal Medicine</i> , 2018, 57, 1655-1659.	0.7	4
339	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1268-1275.	0.9	43
340	Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1923-1932.	5.6	26
341	Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. <i>Frontiers in Immunology</i> , 2018, 9, 1510.	4.8	89
342	Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. <i>Scientific Reports</i> , 2018, 8, 10262.	3.3	54

#	ARTICLE	IF	CITATIONS
343	Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. <i>Clinical Immunology</i> , 2018, 195, 1-7.	3.2	66
344	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018, 392, 222-231.	13.7	396
345	Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. <i>Arthritis Research and Therapy</i> , 2018, 20, 151.	3.5	12
346	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. <i>Inflammation and Regeneration</i> , 2018, 38, 4.	3.7	32
347	Effects of hypergravity on the gene expression of the hypothalamic feeding-related neuropeptides in mice via vestibular inputs. <i>Peptides</i> , 2018, 105, 14-20.	2.4	3
348	Hyperparathyroidism-jaw Tumor Syndrome Confirmed by Preoperative Genetic Testing. <i>Internal Medicine</i> , 2018, 57, 841-844.	0.7	10
349	Risk Factors of Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 603-612.	4.4	28
350	Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1354-1361.	0.9	62
351	Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 137-142.	0.7	0
352	Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 462-470.	0.8	5
353	Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. <i>Advances in Therapy</i> , 2017, 34, 686-702.	2.9	21
354	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1253-1262.	0.9	316
355	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1348-1356.	0.9	36
356	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. <i>Lancet, The</i> , 2017, 389, 1206-1217.	13.7	94
357	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 652-662.	27.0	643
358	Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. <i>Rheumatology</i> , 2017, 56, 1293-1301.	1.9	19
359	Metabolic Reprogramming Commits Differentiation of Human CD27 <sup>+</sup> IgD <sup>+</sup> B Cells to Plasmablasts or CD27 <sup>hi</sup> IgD <sup>hi</sup> Cells. <i>Journal of Immunology</i> , 2017, 199, 425-434.	0.8	72
360	Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2029-2037.	5.6	74

#	ARTICLE	IF	CITATIONS
361	The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases. <i>Modern Rheumatology Case Reports</i> , 2017, 1, 108-112.	0.7	1
362	Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. <i>Arthritis Research and Therapy</i> , 2017, 19, 56.	3.5	12
363	Determinants of hemoglobin A1c level in patients with type 2 diabetes after in-hospital diabetes education: A study based on continuous glucose monitoring. <i>Journal of Diabetes Investigation</i> , 2017, 8, 314-320.	2.4	8
364	Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus. <i>Scientific Reports</i> , 2017, 7, 12566.	3.3	22
365	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. <i>Arthritis and Rheumatology</i> , 2017, 69, 1960-1968.	5.6	182
366	Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 49-54.	1.1	4
367	Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells. <i>Journal of Immunology</i> , 2017, 199, 1616-1625.	0.8	53
368	Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells. <i>Thyroid</i> , 2017, 27, 1335-1336.	4.5	17
369	DMARD de-escalation "let the patient guide you. <i>Nature Reviews Rheumatology</i> , 2017, 13, 637-638.	8.0	14
370	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1853-1861.	0.9	83
371	A case of rheumatoid arthritis treated with infliximab who developed disseminated <i>Penicillium marneffeii</i> infection after visit to Thailand. <i>Modern Rheumatology Case Reports</i> , 2017, 1, 43-48.	0.7	4
372	Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. <i>Scientific Reports</i> , 2017, 7, 15035.	3.3	23
373	A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. <i>Modern Rheumatology</i> , 2017, 27, 849-854.	1.8	62
374	Factors influencing interday glycemic variability in diabetic outpatients receiving insulin therapy. <i>Journal of Diabetes Investigation</i> , 2017, 8, 69-74.	2.4	22
375	Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. <i>Modern Rheumatology</i> , 2017, 27, 284-291.	1.8	7
376	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. <i>Modern Rheumatology</i> , 2017, 27, 237-245.	1.8	54
377	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio study. <i>Modern Rheumatology</i> , 2017, 27, 217-226.	1.8	26
378	Role of P-glycoprotein on CD69+CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy. <i>RMD Open</i> , 2017, 3, e000423.	3.8	10

#	ARTICLE	IF	CITATIONS
379	The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2017, 56, 1301-1306.	0.7	10
380	Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 60.	2.7	10
381	Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2017, 64, 179-189.	1.6	5
382	Introducing the launch of Modern Rheumatology Case Reports. <i>Modern Rheumatology Case Reports</i> , 2017, 1, 1-1.	0.7	0
383	Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis. <i>Internal Medicine</i> , 2017, 56, 1575-1580.	0.7	2
384	Clinical Features of Patients with Basedow's Disease and High Serum IgG4 Levels. <i>Internal Medicine</i> , 2017, 56, 1009-1013.	0.7	13
385	Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 562-570.	0.8	16
386	Current concepts in the management of rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 210-218.	1.7	67
387	Overexpression of Peroxiredoxin 4 Affects Intestinal Function in a Dietary Mouse Model of Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0152549.	2.5	28
388	Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2016, 55, 3091-3095.	0.7	12
389	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
390	Response to: "Denosumab, cortical bone and bone erosion in rheumatoid arthritis"™ by Rossini et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e71-e71.	0.9	2
391	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1917-1923.	0.9	81
392	Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1â€¦year outcomes of the HOPEFUL-2 study. <i>RMD Open</i> , 2016, 2, e000189.	3.8	21
393	Usefulness of nailfold videocapillaroscopy for systemic sclerosis. <i>Inflammation and Regeneration</i> , 2016, 36, 5.	3.7	7
394	Effect of denosumab on Japanese patients with rheumatoid arthritis: a doseâ€¦response study of AMG 162 (<i>D</i>enosumab) in patients with <i>R</i>heumato<i>I</i>d arthritis on methotrexate to <i>V</i>alidate inhibitory effect on bone <i>E</i>rosion (DRIVE)â€¦a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 983-990.	0.9	157
395	Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1428-1437.	0.9	232
396	Chemical JAK inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2215-2225.	1.8	22

#	ARTICLE	IF	CITATIONS
397	Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial) <i>TJ ETQq1 1 078431442 BT / Over</i>	1.9	26
398	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1216-1225.	1.9	26
399	Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. <i>BioDrugs</i> , 2016, 30, 407-419.	4.6	52
400	Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, ii15-ii22.	1.9	21
401	Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes. <i>Endocrine Journal</i> , 2016, 63, 431-440.	1.6	14
402	BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. <i>Inflammation and Regeneration</i> , 2016, 36, 6.	3.7	42
403	Baricitinib for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 911-919.	3.0	29
404	Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study. <i>BMJ Open</i> , 2016, 6, e011183.	1.9	20
405	Response to Dr Minota's Letter to the Editor of <i>Modern Rheumatology</i> Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis. <i>Modern Rheumatology</i> , 2016, 26, 318-319.	1.8	0
406	Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. <i>Arthritis Research and Therapy</i> , 2016, 18, 34.	3.5	117
407	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). <i>Rheumatology and Therapy</i> , 2016, 3, 129-141.	2.3	3
408	B-cell subsets, signaling and their roles in secretion of autoantibodies. <i>Lupus</i> , 2016, 25, 850-856.	1.6	54
409	Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1047-1057.	3.0	33
410	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 491-498.	1.8	80
411	Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome. <i>Modern Rheumatology</i> , 2016, 26, 716-724.	1.8	21
412	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1057-1064.	0.9	125
413	Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study. <i>Modern Rheumatology</i> , 2016, 26, 87-93.	1.8	16
414	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. <i>Modern Rheumatology</i> , 2016, 26, 15-23.	1.8	53



#	ARTICLE	IF	CITATIONS
415	Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. <i>Journal of Rheumatology</i> , 2016, 43, 504-511.	2.0	110
416	Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 319-326.	3.3	7
417	Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study. <i>Diabetology International</i> , 2016, 7, 368-374.	1.4	8
418	Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. <i>Modern Rheumatology</i> , 2016, 26, 850-856.	1.8	14
419	Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016, 26, 473-480.	1.8	9
420	Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab. <i>Modern Rheumatology</i> , 2016, 26, 807-812.	1.8	8
421	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study. <i>Modern Rheumatology</i> , 2016, 26, 651-661.	1.8	24
422	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1321-1327.	0.9	42
423	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 75-83.	0.9	94
424	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial. <i>Modern Rheumatology</i> , 2016, 26, 481-490.	1.8	13
425	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. <i>Modern Rheumatology</i> , 2016, 26, 323-330.	1.8	6
426	Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early Diagnosis and Treatment of Osteoporosis in Japan (EDITOR-J) study. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 646-654.	2.7	15
427	Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia. <i>European Radiology</i> , 2016, 26, 1056-1063.	4.5	16
428	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. <i>Modern Rheumatology</i> , 2016, 26, 80-86.	1.8	40
429	Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold. <i>PLoS ONE</i> , 2016, 11, e0153231.	2.5	46
430	Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 160020.	0.5	5
431	Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 49-52.	0.8	14
432	Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 834-841.	0.8	4

#	ARTICLE	IF	CITATIONS
433	A multi-biomarker disease activity score for monitoring rheumatoid arthritis. <i>Current Biomarker Findings</i> , 2015, , 69.	0.4	2
434	Histamine inhibits differentiation of skin fibroblasts into myofibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 434-439.	2.1	16
435	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. <i>Modern Rheumatology</i> , 2015, 25, 11-20.	1.8	11
436	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. <i>Arthritis Research and Therapy</i> , 2015, 17, 74.	3.5	53
437	Combination therapy for early rheumatoid arthritis: a treatment holiday perspective. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 115-122.	3.1	4
438	Contribution of the Interleukin-6/STAT3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells. <i>Arthritis and Rheumatology</i> , 2015, 67, 1250-1260.	5.6	82
439	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2015, 25, 817-824.	1.8	69
440	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. <i>Modern Rheumatology</i> , 2015, 25, 344-349.	1.8	17
441	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. <i>Modern Rheumatology</i> , 2015, 25, 514-521.	1.8	109
442	Activation of Syk in Peripheral Blood B Cells in Patients With Rheumatoid Arthritis: A Potential Target for Abatacept Therapy. <i>Arthritis and Rheumatology</i> , 2015, 67, 63-73.	5.6	59
443	Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 695-704.	1.6	38
444	Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. <i>Journal of Biochemistry</i> , 2015, 158, 173-179.	1.7	63
445	Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 208-218.	1.9	19
446	Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2015, 14, 25.	6.8	38
447	Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Oencia Trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial—an open-label, one-year, prospective study—Interim analysis of 32 patients for 24 weeks. <i>Modern Rheumatology</i> , 2015, 25, 187-193.	1.8	34
448	Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation. <i>Rheumatology</i> , 2015, 54, 1488-1497.	1.9	41
449	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. <i>Journal of Rheumatology</i> , 2015, 42, 799-809.	2.0	39
450	Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 614-622.	2.0	8

#	ARTICLE	IF	CITATIONS
451	Serum 14-3-3 $\beta$ level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. <i>Arthritis Research and Therapy</i> , 2015, 17, 280.	3.5	27
452	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 389-395.	0.9	149
453	Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 405-412.	1.9	55
454	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. <i>Rheumatology</i> , 2015, 54, 683-691.	1.9	39
455	Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis. <i>World Journal of Experimental Medicine</i> , 2015, 5, 225.	1.7	21
456	Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S58-62.	0.8	25
457	Local Delivery of Mesenchymal Stem Cells with Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold Suppress Arthritis in Rats. <i>PLoS ONE</i> , 2014, 9, e114621.	2.5	21
458	The possible mode of action of Tofacitinib, a JAK inhibitor. <i>Inflammation and Regeneration</i> , 2014, 34, 129-133.	3.7	1
459	<i>Clinical Trials Express:</i>Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2599-2607.	3.6	138
460	Efficacy and safety of reducing duration of infliximab infusion. <i>Modern Rheumatology</i> , 2014, 24, 275-280.	1.8	4
461	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2014, 24, 552-560.	1.8	40
462	Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. <i>Modern Rheumatology</i> , 2014, 24, 405-409.	1.8	29
463	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. <i>Modern Rheumatology</i> , 2014, 24, 42-51.	1.8	11
464	Acquiring Chondrocyte Phenotype from Human Mesenchymal Stem Cells under Inflammatory Conditions. <i>International Journal of Molecular Sciences</i> , 2014, 15, 21270-21285.	4.1	22
465	Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. <i>Modern Rheumatology</i> , 2014, 24, 399-404.	1.8	15
466	Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan. <i>Journal of Rheumatology</i> , 2014, 41, 15-23.	2.0	174
467	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. <i>Modern Rheumatology</i> , 2014, 24, 390-398.	1.8	100
468	Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2213-2215.	0.9	38

#	ARTICLE	IF	CITATIONS
469	Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis. <i>Drugs</i> , 2014, 74, 2129-2139.	10.9	15
470	IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1595-1597.	0.9	84
471	Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2014, 13, 99.	6.8	18
472	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. <i>Modern Rheumatology</i> , 2014, 24, 734-743.	1.8	11
473	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. <i>Modern Rheumatology</i> , 2014, 24, 725-733.	1.8	12
474	Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. <i>Rheumatology</i> , 2014, 53, 904-913.	1.9	27
475	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2014, 24, 715-724.	1.8	49
476	Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. <i>Rheumatology</i> , 2014, 53, 914-918.	1.9	40
477	A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. <i>Journal of Bone and Mineral Metabolism</i> , 2014, 32, 601-604.	2.7	12
478	IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent. <i>Rheumatology</i> , 2014, 53, 1282-1290.	1.9	52
479	Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2014, 5, 313-319.	2.4	84
480	Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 103-113.	1.8	17
481	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 536-543.	0.9	82
482	Prophylaxis for <i>Pneumocystis pneumonia</i> in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. <i>Arthritis Research and Therapy</i> , 2014, 16, R43.	3.5	58
483	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orenzia <sup>®</sup> as Biological Intensive Treatment for RA (ORBIT) study. <i>Modern Rheumatology</i> , 2014, 24, 754-762.	1.8	15
484	Systemic Lupus Erythematosus. <i>Academic Radiology</i> , 2014, 21, 617-623.	2.5	2
485	The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2192-2198.	0.9	136
486	The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. <i>Rheumatology International</i> , 2014, 34, 1729-1736.	3.0	14

#	ARTICLE	IF	CITATIONS
487	The non-canonical Wnt5a/Ror2 signaling pathway in bone metabolism. <i>Inflammation and Regeneration</i> , 2014, 34, 103-108.	3.7	2
488	Clinical characteristics and risk factors for <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. <i>Modern Rheumatology</i> , 2013, 23, 1085-93.	1.8	18
489	Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 89-95.	2.7	15
490	A case of multiple brown tumors with primary hyperparathyroidism. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 123-127.	2.7	15
491	Dopamine D2-like receptor signaling suppresses human osteoclastogenesis. <i>Bone</i> , 2013, 56, 1-8.	2.9	45
492	Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?. <i>Clinical Therapeutics</i> , 2013, 35, 2028-2035.	2.5	22
493	Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. <i>Arthritis Research and Therapy</i> , 2013, 15, R135.	3.5	39
494	Efficacy of combination of Ezetimibe 10mg and rosuvastatin 2.5mg versus rosuvastatin 5mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. <i>Lipids in Health and Disease</i> , 2013, 12, 137.	3.0	39
495	Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. <i>Modern Rheumatology</i> , 2013, 23, 401-405.	1.8	4
496	Tofacitinib (CPA690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013, 65, 559-570.	6.7	481
497	Efficacy of glucosidase inhibitors combined with dipeptidylpeptidase4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring. <i>Journal of Diabetes Investigation</i> , 2013, 4, 393-398.	2.4	13
498	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. <i>Rheumatology</i> , 2013, 52, 1202-1207.	1.9	79
499	Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2013, 12, 1.	6.8	215
500	Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. <i>Diabetology International</i> , 2013, 4, 117-125.	1.4	5
501	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. <i>The ALTAIR study. Modern Rheumatology</i> , 2013, , 1.	1.8	0
502	Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii124-ii127.	0.9	44
503	Janus kinase inhibitors in autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii111-ii115.	0.9	350
504	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , 2013, 23, 1045-1052.	1.8	7

#	ARTICLE	IF	CITATIONS
505	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. <i>Modern Rheumatology</i> , 2013, 23, 945-952.	1.8	20
506	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1488-1495.	0.9	51
507	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.9	102
508	Clinical characteristics and risk factors for <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. <i>Modern Rheumatology</i> , 2013, 23, 1085-1093.	1.8	28
509	Safety and Effectiveness of 6 Months Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2013, 40, 1658-1668.	2.0	12
510	Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients. <i>Modern Rheumatology</i> , 2013, 23, 219-225.	1.8	22
511	Activation of Wnt5a or 2 signaling associated with epithelial to mesenchymal transition of tubular epithelial cells during renal fibrosis. <i>Genes To Cells</i> , 2013, 18, 608-619.	1.2	35
512	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. <i>Modern Rheumatology</i> , 2013, 23, 415-424.	1.8	53
513	Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. <i>Endocrine Journal</i> , 2013, 60, 563-570.	1.6	13
514	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. <i>Modern Rheumatology</i> , 2013, 23, 1151-1157.	1.8	16
515	IL-17 Inhibits Chondrogenic Differentiation of Human Mesenchymal Stem Cells. <i>PLoS ONE</i> , 2013, 8, e79463.	2.5	42
516	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. <i>Modern Rheumatology</i> , 2013, 23, 415-424.	1.8	27
517	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. <i>Modern Rheumatology</i> , 2013, 23, 1151-7.	1.8	8
518	4. Drugs Targeting Intracellular Molecule: JAK Inhibitor and Syk Inhibitor. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 44, 23-27.	0.1	0
519	Regulatory role of mesenchymal stem cells in osteoclast differentiation. <i>Inflammation and Regeneration</i> , 2013, 33, 217-222.	3.7	1
520	Role of JAKs in myeloid cells and autoimmune diseases. <i>Inflammation and Regeneration</i> , 2013, 33, 131-135.	3.7	0
521	Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. <i>Modern Rheumatology</i> , 2013, 23, 401-405.	1.8	3
522	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , 2013, 23, 1045-52.	1.8	2

#	ARTICLE	IF	CITATIONS
523	Discontinuation of biologics in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S22-7.	0.8	91
524	Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 2058-2059.	0.9	13
525	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 817-824.	0.9	102
526	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , 2012, 22, 327-338.	1.8	38
527	Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1820-1826.	0.9	47
528	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. <i>Modern Rheumatology</i> , 2012, 22, 21-30.	1.8	1,294
529	B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1749-1750.	0.9	11
530	Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 319-326.	4.3	44
531	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. <i>Modern Rheumatology</i> , 2012, 22, 1-14.	1.8	662
532	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/ $\beta$ 2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. <i>Modern Rheumatology</i> , 2012, 22, 769-773.	1.8	4
533	Cell-autonomous role of TGF $\beta$ 2 and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. <i>Blood</i> , 2012, 119, 5575-5583.	1.4	42
534	<i>Pneumocystis jirovecii</i> pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. <i>Modern Rheumatology</i> , 2012, 22, 849-858.	1.8	46
535	Signal transduction inhibitors for the treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, .	3.5	0
536	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. <i>Modern Rheumatology</i> , 2012, 22, 498-508.	1.8	81
537	Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. <i>Modern Rheumatology</i> , 2012, 22, 382-393.	1.8	71
538	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. <i>Modern Rheumatology</i> , 2012, 22, 814-822.	1.8	29
539	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012, 22, 186-194.	1.8	6
540	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/ $\beta$ 2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. <i>Modern Rheumatology</i> , 2012, 22, 769-773.	1.8	2

#	ARTICLE	IF	CITATIONS
541	Interleukin-1 $\beta$ induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway. <i>Arthritis and Rheumatism</i> , 2012, 64, 3355-3363.	6.7	132
542	Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1594-1601.e2.	2.9	43
543	Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients. <i>Advances in Therapy</i> , 2012, 29, 635-644.	2.9	27
544	Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1125-1134.	3.4	47
545	The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon- $\gamma$ and interleukin-17 production by human CD4+ T cells. <i>Arthritis and Rheumatism</i> , 2012, 64, 1790-1798.	6.7	196
546	Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 102-108.	1.6	26
547	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. <i>Modern Rheumatology</i> , 2012, 22, 1-14.	1.8	453
548	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , 2012, 22, 327-338.	1.8	26
549	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. <i>Modern Rheumatology</i> , 2012, 22, 21-30.	1.8	947
550	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. <i>Modern Rheumatology</i> , 2012, 22, 814-822.	1.8	21
551	Mesenchymal stem cells: A new treatment tool for rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2012, 32, 188-192.	3.7	1
552	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012, 22, 186-194.	1.8	2
553	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). <i>Modern Rheumatology</i> , 2011, 21, 122-133.	1.8	65
554	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011, 21, 343-351.	1.8	95
555	Efficacité de l'etanercept dans une cirrhose biliaire primitive associée à une polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2011, 78, 589-590.	0.0	0
556	Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. <i>Journal of Rheumatology</i> , 2011, 38, 1258-1264.	2.0	141
557	Recent progress in small molecular products for the treatment of joint and bone diseases: an overview. <i>Inflammation and Regeneration</i> , 2011, 31, 341-343.	3.7	0
558	JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug. <i>Inflammation and Regeneration</i> , 2011, 31, 349-353.	3.7	1



#	ARTICLE	IF	CITATIONS
559	Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2011, 78, 99-100.	1.6	2
560	Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2011, 78, 535-536.	1.6	9
561	Phase II study of tofacitinib (CPâ€690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. <i>Arthritis Care and Research</i> , 2011, 63, 1150-1158.	3.4	259
562	Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. <i>Arthritis and Rheumatism</i> , 2011, 63, 1658-1667.	6.7	73
563	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2148-2151.	0.9	166
564	Phenotypic Changes of Lymphocytes in Patients with Systemic Lupus Erythematosus Who Are in Longterm Remission After B Cell Depletion Therapy with Rituximab. <i>Journal of Rheumatology</i> , 2011, 38, 633-641.	2.0	60
565	Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study. <i>Journal of Rheumatology</i> , 2011, 38, 1585-1592.	2.0	75
566	Efficacy of combination therapy of anti-TNF-Î± antibody infliximab and methotrexate in refractory entero-BeHÅŞetâ€™s disease. <i>Modern Rheumatology</i> , 2011, 21, 184-191.	1.8	69
567	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDsâ€™a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011, 21, 458-468.	1.8	21
568	Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patientsâ€“REACTION 52-week study. <i>Rheumatology</i> , 2011, 50, 1908-1915.	1.9	78
569	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011, 21, 444-448.	1.8	16
570	Efficacy of combination therapy of anti-TNF-Î± antibody infliximab and methotrexate in refractory entero-BeHÅŞetâ€™s disease. <i>Modern Rheumatology</i> , 2011, 21, 184-191.	1.8	50
571	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011, 21, 343-351.	1.8	51
572	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDsâ€™a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011, 21, 458-468.	1.8	12
573	Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases. <i>Inflammation and Regeneration</i> , 2011, 31, 237-244.	3.7	6
574	Denosumab for the treatment of joint and bone diseases. <i>Inflammation and Regeneration</i> , 2011, 31, 344-348.	3.7	1
575	C5a promotes migration, proliferation, and vessel formation in endothelial cells. <i>Inflammation Research</i> , 2010, 59, 659-666.	4.0	38
576	Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. <i>FEBS Letters</i> , 2010, 584, 61-66.	2.8	100

#	ARTICLE	IF	CITATIONS
577	Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling. <i>Arthritis and Rheumatism</i> , 2010, 62, 952-959.	6.7	46
578	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010, 20, 139-146.	1.8	20
579	Tacrolimus, a Calcineurin Inhibitor, Overcomes Treatment Unresponsiveness Mediated by P-glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 512-520.	2.0	56
580	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1286-1291.	0.9	251
581	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , 2010, 20, 531-538.	1.8	60
582	Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 317-322.	2.1	47
583	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010, 20, 139-146.	1.8	10
584	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , 2010, 20, 531-538.	1.8	43
585	Effects of anti-TNF- $\alpha$ antibody infliximab in refractory entero-Behcet's disease. <i>Rheumatology</i> , 2009, 48, 1012-1013.	1.9	51
586	Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. <i>Journal of Rheumatology</i> , 2009, 36, 898-906.	2.0	167
587	Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy. <i>Rheumatology</i> , 2009, 48, 1279-1282.	1.9	20
588	Interaction of Galectin-9 With Lipid Rafts Induces Osteoblast Proliferation Through the c-Src/ERK Signaling Pathway. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 278-286.	2.8	33
589	Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis. <i>Biochemical and Biophysical Research Communications</i> , 2008, 373, 286-291.	2.1	131
590	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 146-152.	1.8	61
591	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , 2008, 18, 460-464.	1.8	42
592	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 447-454.	1.8	40
593	Alendronate Protects Premenopausal Women from Bone Loss and Fracture Associated with High-dose Glucocorticoid Therapy. <i>Journal of Rheumatology</i> , 2008, 35, 2249-2254.	2.0	50
594	Reply to Dr Pollono. <i>Endocrine Journal</i> , 2008, 55, 949.	1.6	0

#	ARTICLE	IF	CITATIONS
595	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 146-152.	1.8	43
596	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008, 18, 447-454.	1.8	29
597	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. <i>Modern Rheumatology</i> , 2008, 18, 460-464.	1.8	32
598	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2007, 17, 481-485.	1.8	15
599	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2007, 17, 191-197.	1.8	107
600	Leflunomide Inhibits PDK1/Akt Pathway and Induces Apoptosis of Human Mast Cells. <i>Journal of Immunology</i> , 2007, 179, 6479-6484.	0.8	40
601	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007, 17, 28-32.	1.8	56
602	Treatment of Inflammatory Immunologic Disease 4. B Cell Targeting Therapy Using the Anti-CD20 Antibody Rituximab in Inflammatory Autoimmune Diseases. <i>Internal Medicine</i> , 2007, 46, 1313-1315.	0.7	18
603	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. <i>Modern Rheumatology</i> , 2007, 17, 464-469.	1.8	33
604	Small GTPase Rho signaling is involved in $\alpha 21$ integrin-mediated up-regulation of intercellular adhesion molecule 1 and receptor activator of nuclear factor $\kappa B$ ligand on osteoblasts and osteoclast maturation. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 279-285.	2.1	13
605	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate. <i>Modern Rheumatology</i> , 2007, 17, 144-147.	1.8	10
606	Activation signal transduction by $\alpha 21$ integrin in T cells from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1559-1568.	6.7	25
607	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007, 17, 28-32.	1.8	46
608	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2007, 17, 191-197.	1.8	92
609	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. <i>Modern Rheumatology</i> , 2007, 17, 464-469.	1.8	24
610	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2007, 17, 481-485.	1.8	10
611	Acetylation of an Ets Transcription Factor PU.1 Suppresses Its Transcriptional Activity.. <i>Blood</i> , 2007, 110, 2402-2402.	1.4	0
612	Glycated albumin and cross-linking of CD44 induce scavenger receptor expression and uptake of oxidized LDL in human monocytes. <i>Biochemical and Biophysical Research Communications</i> , 2006, 339, 846-851.	2.1	13

#	ARTICLE	IF	CITATIONS
613	Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. <i>Biochemical and Biophysical Research Communications</i> , 2006, 344, 780-785.	2.1	64
614	Anti-CD20 and other novel biotherapies for systemic lupus erythematosus. <i>APLAR Journal of Rheumatology</i> , 2006, 9, 413-418.	0.2	3
615	Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125. <i>Genes To Cells</i> , 2006, 11, 983-992.	1.2	11
616	Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients. <i>Autoimmunity Reviews</i> , 2006, 5, 143-144.	5.8	15
617	Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 470-475.	0.9	282
618	Fragmented Hyaluronan Induces Transcriptional Up-regulation of the Multidrug Resistance-1 Gene in CD4+ T Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 38089-38097.	3.4	19
619	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. <i>Modern Rheumatology</i> , 2005, 15, 374-380.	1.8	5
620	Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 52, 1676-1683.	6.7	80
621	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2005, 15, 28-32.	1.8	15
622	Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 325-328.	3.1	321
623	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. <i>Modern Rheumatology</i> , 2005, 15, 163-168.	1.8	9
624	Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts. <i>Arthritis Research</i> , 2005, 7, R476.	2.0	16
625	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2005, 15, 28-32.	1.8	14
626	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. <i>Modern Rheumatology</i> , 2005, 15, 163-168.	1.8	5
627	Effects of oxygen therapy during sleep in chronic dialysis patients with sleep-disordered breathing. <i>Nihon Toseki Igakkai Zasshi</i> , 2005, 38, 1187-1194.	0.1	0
628	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. <i>Modern Rheumatology</i> , 2005, 15, 374-380.	1.8	6
629	Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. <i>Genes To Cells</i> , 2004, 9, 1265-1273.	1.2	57
630	Macrophage Inflammatory Protein-1 $\alpha$ Induces Hypercalcemia in Adult T-Cell Leukemia. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1105-1111.	2.8	42

#	ARTICLE	IF	CITATIONS
631	Acro-Osteolysis and Symphalangism Mutations. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 160-160.	2.8	0
632	Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13 in Japanese. <i>Journal of Human Genetics</i> , 2004, 49, 629-634.	2.3	18
633	Severe hypercalcemia and hyponatremia associated with calcipotriol for treatment of psoriasis. <i>Journal of Bone and Mineral Metabolism</i> , 2004, 22, 159-162.	2.7	16
634	Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2004, 50, 2450-2458.	6.7	61
635	Expression of the Chk2 Gene Is Downregulated in Hodgkin's Lymphoma Cell Lines Via Epigenetic Mechanisms. <i>Blood</i> , 2004, 104, 429-429.	1.4	0
636	Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. <i>Journal of Rheumatology</i> , 2004, 31, 163-6.	2.0	28
637	Adult-Onset Idiopathic Progressive Acro-Osteolysis With Proximal Symphalangism. <i>Journal of Bone and Mineral Research</i> , 2003, 19, 165-167.	2.8	7
638	Inter- and intracellular signaling in secondary osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , 2003, 21, 61-66.	2.7	13
639	$\alpha$ 1 integrin-mediated signaling induces intercellular adhesion molecule 1 and Fas on rheumatoid synovial cells and Fas-mediated apoptosis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1239-1248.	6.7	32
640	Crosslinking of CD44 on human osteoblastic cells upregulates ICAM-1 and VCAM-1. <i>FEBS Letters</i> , 2003, 539, 45-50.	2.8	36
641	Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 380-385.	2.1	49
642	Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial. <i>Modern Rheumatology</i> , 2003, 13, 339-345.	1.8	12
643	Severe skin ulceration associated with Wegener's granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E <sub>1</sub> . <i>Modern Rheumatology</i> , 2003, 13, 346-349.	1.8	0
644	$\alpha$ 1 Integrin/Focal Adhesion Kinase-mediated Signaling Induces Intercellular Adhesion Molecule 1 and Receptor Activator of Nuclear Factor $\kappa$ B Ligand on Osteoblasts and Osteoclast Maturation. <i>Journal of Biological Chemistry</i> , 2003, 278, 45368-45374.	3.4	68
645	Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial. <i>Modern Rheumatology</i> , 2003, 13, 339-345.	1.8	2
646	Severe skin ulceration associated with Wegener's granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E <sub>1</sub> . <i>Modern Rheumatology</i> , 2003, 13, 346-349.	1.8	0
647	Autocrine Induction of the Human Pro-IL-1 $\beta$ Gene Promoter by IL-1 $\beta$ in Monocytes. <i>Journal of Immunology</i> , 2002, 168, 1984-1991.	0.8	60
648	H-Ras/Mitogen-activated Protein Kinase Pathway Inhibits Integrin-mediated Adhesion and Induces Apoptosis in Osteoblasts. <i>Journal of Biological Chemistry</i> , 2002, 277, 21446-21452.	3.4	39

#	ARTICLE	IF	CITATIONS
649	Hypoxia-inducible factor-1 $\alpha$ induces cell cycle arrest of endothelial cells. <i>Genes To Cells</i> , 2002, 7, 143-149.	1.2	63
650	Clinical implication of cyclosporin for systemic autoimmune diseases: relevance to multidrug resistance. <i>Japanese Journal of Clinical Immunology</i> , 2002, 25, 110-114.	0.0	1
651	<i>Pneumocystis carinii</i> pneumonia in patients with connective tissue diseases. <i>Japanese Journal of Clinical Immunology</i> , 2002, 25, 310-318.	0.0	3
652	Activated Platelets and Endothelial Cell Interaction with Neutrophils under Flow Conditions.. <i>Internal Medicine</i> , 2001, 40, 1085-1092.	0.7	41
653	Fractalkine, a CX3C chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. <i>Immunology and Cell Biology</i> , 2001, 79, 298-302.	2.3	86
654	Down-regulation of $\alpha 6$ integrin, an anti-oncogene product, by functional cooperation of H-Ras and c-Myc. <i>Genes To Cells</i> , 2001, 6, 337-343.	1.2	12
655	CD44 Is the Physiological Trigger of Fas Up-Regulation on Rheumatoid Synovial Cells. <i>Journal of Immunology</i> , 2001, 167, 1198-1203.	0.8	67
656	CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. <i>International Immunology</i> , 2001, 13, 1309-1319.	4.0	58
657	The role of chemokines and adhesion molecules in the pathogenesis of rheumatoid arthritis. <i>Drugs of Today</i> , 2001, 37, 477.	2.4	21
658	Intercellular adhesion molecule 1 underlies the functional heterogeneity of synovial cells in patients with rheumatoid arthritis: Involvement of cell cycle machinery. <i>Arthritis and Rheumatism</i> , 2000, 43, 2513-2522.	6.7	10
659	Intercellular Adhesion Molecule 1 Discriminates Functionally Different Populations of Human Osteoblasts: Characteristic Involvement of Cell Cycle Regulators. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 1912-1923.	2.8	80
660	Constitutive activation of LIL-Stat in adult T-cell leukemia cells. <i>Blood</i> , 2000, 95, 2715-2718.	1.4	8
661	Intercellular adhesion molecule-1 (ICAM-1) mediated gene delivery to rheumatoid synovial cells using the Fab fragments of anti-ICAM-1 monoclonal antibody. <i>Japanese Journal of Clinical Immunology</i> , 2000, 23, 533-537.	0.0	1
662	Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis. <i>Modern Rheumatology</i> , 2000, 10, 103-109.	1.8	1
663	Activation of Leukocyte Function-Associated Antigen-1 on Adult T-cell Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1999, 36, 15-23.	1.3	13
664	H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. <i>Journal of Immunology</i> , 1999, 163, 6209-16.	0.8	57
665	Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis. <i>Arthritis and Rheumatism</i> , 1998, 41, 1365-1377.	6.7	51
666	Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. , 1998, 75, 391-395.		15

#	ARTICLE	IF	CITATIONS
667	A Critical Role for Cyclin C in Promotion of the Hematopoietic Cell Cycle by Cooperation with c-Myc. <i>Molecular and Cellular Biology</i> , 1998, 18, 3445-3454.	2.3	41
668	Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia Cells. <i>Blood</i> , 1998, 91, 3909-3919.	1.4	75
669	Chemokine and Cellular Adhesion in the Context of Heparan Sulfate Proteoglycan.. <i>Trends in Glycoscience and Glycotechnology</i> , 1998, 10, 153-160.	0.1	5
670	Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells. <i>Cancer Research</i> , 1998, 58, 4138-45.	0.9	27
671	Chondrocytes Are Regulated by Cellular Adhesion Through CD44 and Hyaluronic Acid Pathway. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1657-1663.	2.8	132
672	Distinct phenotype of leukemic T cells with various tissue tropisms. <i>Journal of Immunology</i> , 1997, 158, 3822-9.	0.8	39
673	Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1462-1469.	2.8	97
674	CD45RB expression defines two interconvertible subsets of human CD4+ T cells with memory function. <i>European Journal of Immunology</i> , 1994, 24, 1240-1243.	2.9	21
675	Differential Expression of Integrins $\alpha 6$ and $\alpha 4$ Determines Pathways in Human Peripheral CD4+ T Cell Differentiation. <i>Cell Adhesion and Communication</i> , 1994, 2, 403-415.	1.7	8
676	Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. <i>Trends in Immunology</i> , 1993, 14, 111-115.	7.5	412
677	T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 $\alpha$ . <i>Nature</i> , 1993, 361, 79-82.	27.8	869
678	Suppressive effect of interleukin-4 on the differentiation of M1 and HL60 myeloid leukemic cells. <i>Journal of Leukocyte Biology</i> , 1993, 54, 133-137.	3.3	5
679	Interleukin-4 induces proliferation of adult T-cell leukemia cells. <i>European Journal of Haematology</i> , 1993, 50, 133-140.	2.2	14
680	Lymphocyte interactions with endothelial cells. <i>Trends in Immunology</i> , 1992, 13, 106-112.	7.5	669
681	B $\alpha$ B Cell Interactions in the Spontaneous Activation of B Cells in Autoimmune NZB Mice. <i>Microbiology and Immunology</i> , 1991, 35, 741-753.	1.4	4
682	Suppressive Activity of Interleukin 4 on the Induction of Antigen-specific Cytotoxic T Cells in Humans. <i>Japanese Journal of Cancer Research</i> , 1991, 82, 585-592.	1.7	10
683	Inhibitory Effect of IL-1 on the TSH Dependent Growth of Rat Thyroid Cells (FRTL-5).. <i>Endocrinologia Japonica</i> , 1990, 37, 619-627.	0.5	5
684	Antiviral and Antiproliferative Activities of Recombinant Human Interferon $\alpha 2$ , $\alpha 2$ and $\alpha 3$ on HTLV- $\alpha$ ... and ATL Cells &lt;i>in Vitro&/i>. <i>Journal of UOEH</i> , 1990, 12, 149-161.	0.6	6

#	ARTICLE	IF	CITATIONS
685	Corrigendum to: Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. <i>Rheumatology</i> , 0, , .	1.9	0